23andMe Holding Co. (ME) Net Profit Margin: -134.54%
Is 23andMe Holding Co.’s net profit margin high or low?
23andMe Holding Co.'s net profit margin of -134.54% is in line with its 5-year average of -132.14%, near the high end of its 5-year range (-303.55%–-75.17%).
As of Monday, June 15, 2026. 40.40% above its 12-month average of -225.74%.
ME Net Profit Margin Chart
ME Average Net Profit Margin Chart
ME Current vs Average Net Profit Margin Chart
ME Net Profit Margin Metrics
NET PROFIT MARGIN
-134.54%
NET PROFIT MARGIN AVG TTM
-225.74%
NET PROFIT MARGIN AVG 3Y
-158.88%
NET PROFIT MARGIN AVG 5Y
-132.14%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+40.40%
CURRENT VS 3Y AVG
+15.32%
CURRENT VS 5Y AVG
-1.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -134.54% | -225.74% | -158.88% | -132.14% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.02B | -17.06% | -20.12% | -16.95% | -10.04% |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.98B | -0.56% | 7.00% | -0.29% | -8.82% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 6.52% | -21.22% | -48.94% | 16.61% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | -22.20% | -60.53% | -62.93% | -77.31% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | -4.59% | -1.67% | 5.09% | 7.31% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -4.07% | -4.03% | -0.72% | 0.14% |
| Baxter International Inc. (BAX)vs › | $10.77B | -9.70% | -7.30% | -3.29% | 1.14% |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 10.50% | 10.36% | 10.48% | 22.21% |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 5.57% | 9.62% | 9.77% | 24.94% |
Margin Comparison
Operating Margin
-114.0%
Net Profit Margin
-134.5%
23andMe Holding Co. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Net Profit Margin FAQ
- What is the net profit margin for 23andMe Holding Co. (ME)?
- The net profit margin for ME stock is -134.54%.
- Is 23andMe Holding Co.'s net profit margin high or low?
- 23andMe Holding Co.'s net profit margin of -134.54% is in line with its 5-year average of -132.14%, near the high end of its 5-year range (-303.55%–-75.17%).
- What is the TTM average net profit margin for 23andMe Holding Co. (ME)?
- The TTM average net profit margin for ME stock is -225.74%.
- What is the 3Y average net profit margin for 23andMe Holding Co. (ME)?
- The 3Y average net profit margin for ME stock is -158.88%.
- What is the 5Y average net profit margin for 23andMe Holding Co. (ME)?
- The 5Y average net profit margin for ME stock is -132.14%.
23andMe Holding Co. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-03-31 | -147.92% |
| 2024-03-31 | -303.55% |
| 2023-03-31 | -104.06% |
| 2022-03-31 | -79.99% |
| 2021-03-31 | -75.17% |
| 2020-03-31 | -82.13% |
| 2019-03-31 | -41.63% |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage